PRDM16 Antibody (174A2D): sc-517625

PRDM16 Antibody (174A2D) is a mouse monoclonal IgG1 kappa light chain antibody that detects PRDM16 protein of human origin by western blotting (WB). Anti-PRDM16 antibody (174A2D) is available as a non-conjugated format. PRDM16, also known as MEL1 or PFM13, is a crucial transcription factor localized in the nucleus, consisting of 1,276 amino acids that feature one SET domain and ten C2H2-type zinc fingers. This unique structure enables PRDM16 to interact with specific DNA sequences, thereby regulating gene expression essential for various cellular processes, including hematopoiesis and adipogenesis. PRDM16 plays a role in the pathogenesis of acute myeloid leukemia and myelodysplastic syndrome, where dysregulation can lead to malignancy. PRDM16 exists in three isoforms due to alternative splicing, which contributes to functional diversity and potential implications in cancer biology. The imbalance between PR-plus and PR-minus products, often resulting from genetic or epigenetic changes, is a critical factor in tumorigenesis, highlighting PRDM16′s importance in cancer research.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PRDM16 Antibody (174A2D) References:

1. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.  |  Mochizuki, N., et al. 2000. Blood. 96: 3209-14. PMID: 11050005
2. Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5' region of MEL1.  |  Xinh, PT., et al. 2003. Genes Chromosomes Cancer. 36: 313-6. PMID: 12557231
3. A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation.  |  Nishikata, I., et al. 2003. Blood. 102: 3323-32. PMID: 12816872
4. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells.  |  Lahortiga, I., et al. 2004. Oncogene. 23: 311-6. PMID: 14712237
5. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.  |  Ott, MG., et al. 2006. Nat Med. 12: 401-9. PMID: 16582916
6. Transcriptional control of brown fat determination by PRDM16.  |  Seale, P., et al. 2007. Cell Metab. 6: 38-54. PMID: 17618855
7. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.  |  Roche-Lestienne, C., et al. 2008. Blood. 111: 3735-41. PMID: 18202228
8. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.  |  Modlich, U., et al. 2008. Leukemia. 22: 1519-28. PMID: 18496560
9. PRDM16 controls a brown fat/skeletal muscle switch.  |  Seale, P., et al. 2008. Nature. 454: 961-7. PMID: 18719582
10. PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis.  |  Zheng, Q., et al. 2024. Redox Biol. 78: 103417. PMID: 39549609
11. Vascular smooth muscle cell PRDM16 regulates circadian variation in blood pressure.  |  Wang, Z., et al. 2024. J Clin Invest.. PMID: 39625782
12. Phytol and bilimbi phytocompounds induce thermogenic adipocyte differentiation: An in vitro study on potential anti-obesity effects.  |  Md Fauzi, F., et al. 2024. Heliyon. 10: e40518. PMID: 39698098